Posted by Defense World Staff on Jul 17th, 2024
StockNews.com assumed coverage on shares of DBV Technologies (NASDAQ:DBVT – Get Free Report) in a research report issued on Wednesday. The brokerage set a “hold” rating on the stock.
Separately, HC Wainwright dropped their price target on shares of DBV Technologies from $20.00 to $10.00 and set a “buy” rating on the stock in a research report on Wednesday, May 8th.
Get Our Latest Research Report on DBV Technologies
DBV Technologies Price Performance
NASDAQ:DBVT opened at $0.83 on Wednesday. The stock’s 50-day moving average is $0.98 and its two-hundred day moving average is $1.39. DBV Technologies has a fifty-two week low of $0.50 and a fifty-two week high of $3.70. The stock has a market cap of $79.68 million, a PE ratio of -0.98 and a beta of 0.69.
DBV Technologies (NASDAQ:DBVT – Get Free Report) last announced its quarterly earnings results on Tuesday, May 7th. The company reported ($0.28) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.44) by $0.16. DBV Technologies had a negative return on equity of 56.76% and a negative net margin of 530.89%. The business had revenue of $1.41 million during the quarter, compared to analyst estimates of $3.20 million. On average, equities research analysts anticipate that DBV Technologies will post -1.22 earnings per share for the current year.
Hedge Funds Weigh In On DBV Technologies
An institutional investor recently bought a new position in DBV Technologies stock. Cowen AND Company LLC acquired a new position in shares of DBV Technologies S.A. (NASDAQ:DBVT – Free Report) in the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm acquired 50,986 shares of the company’s stock, valued at approximately $49,000. 71.74% of the stock is currently owned by institutional investors and hedge funds.
About DBV Technologies
DBV Technologies SA, a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow’s milk protein allergy and eosinophilic esophagitis.
See Also
- Five stocks we like better than DBV Technologies
- How to Invest in Biotech Stocks
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- TSX Venture Exchange (Formerly Canadian Venture Exchange)
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for DBV Technologies Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for DBV Technologies and related companies with MarketBeat.com’s FREE daily email newsletter.
You might be interested in:
